• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Novartis AG (NVS)

Equity
Sell: $156.80|Buy: $160.00|Change: 2.44 (-1.53%)

Open 

$158.41

Previous close 

$159.98

Trade high 

$159.19

Volume 

1,473,551

Year high 

$170.46

Year low 

$121.57

Dividend yield 

2.96%

Market capitalisation 

$299.44 bn

P/E ratio 

24.17

ISIN 

US66987V1098

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date12/03/202511/03/2026
Ex-dividend date12/03/202511/03/2026
Payment date25/04/202516/03/2026
Amount$3.99399$4.74025

Performance 26/08/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Novartis AG- 1.53
More...

Company profile

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.